Axogen (AXGN) Cash from Investing Activities (2010 - 2026)
Axogen's (AXGN) quarterly Cash from Investing Activities came in at -$16.0 million in Q1 2026, down 1292.23% year-on-year from $1.3 million in Q1 2025, and down 494.95% quarter-over-quarter from $4.0 million in Q4 2025.
Axogen (AXGN) Cash from Investing Activities (2010 - 2026) Analysis & Trends
Axogen's Cash from Investing Activities history runs 17 years deep, the most recent figure standing at -$16.0 million for Q1 2026.
- On a quarterly basis, Cash from Investing Activities fell 1292.23% year-over-year to -$16.0 million in Q1 2026; TTM through Mar 2026 was -$22.6 million, a 296.36% decrease from a year earlier, with the FY2025 full-year figure at -$5.3 million, up 48.36% from the prior year.
- Cash from Investing Activities slipped to -$16.0 million in Q1 2026 per AXGN's latest filing, from $4.0 million in the prior quarter.
- Across five years, Cash from Investing Activities topped out at $14.3 million in Q2 2023 and bottomed at -$16.0 million in Q1 2026.
- The 5-year median for Cash from Investing Activities is -$813000.0 (2024), against an average of -$913235.3.
- Across the five-year window, Cash from Investing Activities soared 597.17% in 2025 and sank 1292.23% in 2026, its largest moves.
- Year by year, Cash from Investing Activities stood at -$1.2 million in 2022, then jumped by 77.09% to -$277000.0 in 2023, then tumbled by 193.5% to -$813000.0 in 2024, then surged by 597.17% to $4.0 million in 2025, then sank by 494.95% to -$16.0 million in 2026.
- Per Business Quant, the three latest AXGN Cash from Investing Activities figures stand at -$16.0 million (Q1 2026), $4.0 million (Q4 2025), and -$3.8 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 182.32 Bn | 175.02 Bn | 6.27 Bn | -20.32 Bn |
| 2 | Stryker | 128.75 Bn | 125.88 Bn | 3.81 Bn | -185.00 Mn |
| 3 | Medtronic | 107.83 Bn | 98.61 Bn | 6.41 Bn | -917.00 Mn |
| 4 | Boston Scientific | 67.61 Bn | 66.15 Bn | 3.61 Bn | -591.00 Mn |
| 5 | Edwards Lifesciences | 48.13 Bn | 44.45 Bn | 1.29 Bn | -92.80 Mn |
| 6 | Dexcom | 28.26 Bn | 27.14 Bn | 750.30 Mn | -298.50 Mn |
| 7 | GE HealthCare Technologies | 27.78 Bn | 25.50 Bn | 1.98 Bn | -2.50 Bn |
| 8 | Smith & Nephew | 26.99 Bn | 26.41 Bn | - | - |
| 9 | Koninklijke Philips | 23.92 Bn | 20.80 Bn | 2.07 Bn | -475.32 Mn |
| 10 | Axogen | 2.12 Bn | 2.02 Bn | 46.19 Mn | -15.96 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -15.96 Mn |
| Mar 31, 2026 | -15.96 Mn |
| Dec 31, 2025 | 4.04 Mn |
| Dec 31, 2025 | 4.04 Mn |
| Sep 30, 2025 | -3.75 Mn |
| Sep 30, 2025 | -3.75 Mn |
| Jun 30, 2025 | -6.95 Mn |
| Jun 30, 2025 | -6.95 Mn |
| Mar 31, 2025 | 1.34 Mn |
| Mar 31, 2025 | 1.34 Mn |
| Dec 31, 2024 | -813,000.00 |
| Dec 31, 2024 | -813,000.00 |
| Sep 30, 2024 | -5.00 Mn |
| Sep 30, 2024 | -5.00 Mn |
| Jun 30, 2024 | -1.23 Mn |
| Jun 30, 2024 | -1.23 Mn |
| Mar 31, 2024 | -3.25 Mn |
| Mar 31, 2024 | -3.25 Mn |
| Dec 31, 2023 | -277,000.00 |
| Dec 31, 2023 | -277,000.00 |